

SKYEPHARMA PLC  
Form 6-K  
October 10, 2006

**SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER  
PURSUANT TO RULE 13a - 16 OR 15d - 16 OF  
THE SECURITIES EXCHANGE ACT OF 1934**

For the month of October, 2006

SkyePharma PLC

---

(Translation of registrant's name into English)

SkyePharma PLC, 105 Piccadilly, London W1J 7NJ England

---

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40F.

Form 20-F  Form 40-F

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-

---

Edgar Filing: SKYEPHARMA PLC - Form 6-K

**For immediate release**

**SkyePharma PLC**

**SkyePharma Appoints Company Secretary**

LONDON, ENGLAND, 9 October, 2006 -- SkyePharma PLC (LSE: SKP; Nasdaq: SKYE) today announce Company Secretary.

John is a lawyer with extensive experience in legal and company secretarial roles in listed companies including Medeva, Celltech and Pharmagene. John joined SkyePharma on 1st March this year, combining both roles in the Company.

**For further information please contact:**

**SkyePharma PLC**

Frank Condella, Chief Executive Officer  
Ken Cunningham, Chief Operating Officer  
Sandra Haughton, US Investor Relations

+44 207 491 1

+1 212 753 57

**Buchanan Communications**

Tim Anderson / Mark Court / Rebecca Skye Dietrich

+44 207 466 5

**The Trout Group**

Seth Lewis

+1 617 583 13

**About SkyePharma**

SkyePharma PLC develops pharmaceutical products benefiting from world-leading drug delivery technology and more effective drug formulations. There are now twelve approved products incorporating SkyePharma oral, injectable, inhaled and topical delivery, supported by advanced solubilisation capabilities. [www.skyepharma.com](http://www.skyepharma.com).

END

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**SkyePharma PLC**

By: /s/ Douglas Parkhill

Name: Douglas Parkhill  
Title: Company Secretary

Date: October 9, 2006